SNT 5505
Alternative Names: PXS-5505A; PXS‐5505; SLT-5505; SNT-5505Latest Information Update: 16 Dec 2024
At a glance
- Originator Pharmaxis
- Developer Syntara Limited; University of Rochester
- Class Amines; Antifibrotics; Antineoplastics; Fluorinated hydrocarbons; Quinolones; Small molecules; Sulfones
- Mechanism of Action Protein lysine 6 oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer; Myelofibrosis
- Preclinical Myelodysplastic syndromes
- No development reported Fibrosis; Pancreatic cancer
Most Recent Events
- 10 Dec 2024 Updated efficacy and adverse event data from a phase Ic/IIa trial in Myelofibrosis released by Syntara
- 09 Dec 2023 Pharmacodynamics, efficacy and adverse events data from a phase I/II trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 04 Dec 2023 Pharmaxis is now called Syntara Limited